mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern
Haomeng Wang, Zhao Chen, Zhenghua Wang, Jin Li, Zhihong Yan, Jinbo Yuan, Airu Zhu, Lan Chen, Ye Liu, Chenlong Hu, Ali Zhu, Guowei Li, Yuehu Li, Jie Deng, Liqiao Ma, Xiuwen Sui, Wei Miao, Junqiang Li, Xiuyu Zheng, Jinhua Piao, Yanfeng Yao, Juhong Rao, Chao Shan, Zhiming Yuan, Jincun Zhao, Tao Zhu
Abstract
In order to overcome the pandemic of COVID-19, messenger RNA (mRNA)-based vaccine has been extensively researched as a rapid and versatile strategy. Herein, we described the immunogenicity of mRNA-based vaccines for Beta and the most recent Omicron variants. The homologous mRNA-Beta and mRNA-Omicron and heterologous Ad5-nCoV plus mRNA vaccine exhibited high-level cross-reactive neutralization for Beta, original, Delta, and Omicron variants. It indicated that the COVID-19 mRNA vaccines have great potential in the clinical use against different SARS-CoV-2 variants.